Drug intelligence / Profile preview

XL495

Development stage: Unknown
Lead developer: Exelixis
Modality: Small Molecules
Administration: Oral

Overview

XL495 is a novel, potent small molecule inhibitor of protein kinase membrane associated tyrosine/threonine 1 (PKMYT1), developed by Exelixis for the treatment of advanced solid tumors. PKMYT1 inhibition is synthetically lethal in cancer cells with genetic anomalies that lead to replication stress—a vulnerability not typically present in normal cells. The drug is currently being evaluated in phase 1 clinical trials as both monotherapy and in combination with select cytotoxic agents for patients with locally advanced or metastatic solid tumors who have limited or no remaining standard treatment options.

Targets

PKMYT1 (Protein kinase membrane associated tyrosine/threonine 1)

Beyond the preview

Go deeper on XL495.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XL495.

Explore the full profile